ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer’s Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development

By August 21, 2018News

ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer’s Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development


Lack of PMN310 binding to amyloid deposits in Alzheimer’s brain tissue may eliminate dose-limiting brain swelling seen with BAN2401 and aducanumab

TORONTO, Ontario and CAMBRIDGE, Massachusetts – August 21, 2018  ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced that its lead antibody candidate for Alzheimer’s disease (AD), PMN310, showed no binding to amyloid beta (Aβ) plaque in AD brain samples in stark contrast to BAN2401 and aducanumab which both displayed robust Aβ plaque reactivity. These findings extend the results ProMIS announced in January 2018, showing greater selectivity of PMN310 for Aβ oligomers compared to aducanumab.  Binding of therapeutic antibodies to Aβ deposits in brain tissue, in particular blood vessels, is believed to underlie the development of ARIA (amyloid-related imaging abnormalities; brain swelling and microhemorrhages) in treated AD patients.    

Commenting on these results, ProMIS President and CEO, Elliot Goldstein, MD, stated: “PMN310 was designed to selectively target soluble toxic Aβ oligomers, now widely believed to be a root cause of AD. By not targeting Aβ plaque, especially in and around blood vessels in the brain, we anticipate PMN310 may not be associated with the dose-limiting brain swelling seen with plaque-binding antibody therapeutics like BAN2401 and aducanumab. Confirmation of such an improved safety profile in clinical trials would allow for administration of higher doses to AD patients, thereby potentially leading to greater therapeutic potency of PMN310.”

The binding profile of PMN310 in human AD brain tissues was directly compared to that of BAN2401 and aducanumab in a preclinical study using the technique of immunohistochemistry (IHC). Results of the study showed binding of BAN2401 and aducanumab to Aβ plaque throughout the brain and in association with blood vessels. Conversely, binding of PMN310 to Aβ plaque was not observed in any region of the AD brain tissues.

BAN2401 (Esai/Biogen) and aducanumab (Biogen) appear to target both Aβ plaque and soluble Aβ oligomers. Recent clinical trials with both BAN2401 and aducanumab, reporting a dose-related response curve (i.e., higher doses enabling greater efficacy) support the targeting of Aβ oligomers for the treatment of AD and at the same time indicate that treatment with antibodies also targeting Aβ plaque is associated with dose-limiting brain swelling in a significant percentage of AD patients. We have shown in multiple preclinical studies that PMN310 has the advantage of selectively targeting toxic Aβ oligomers, with no “off-target” binding to Aβ plaque, potentially allowing for the safe administration of higher effective doses of PMN310 compared to BAN2401 or aducanumab.

According to Dr. Goldstein, “Although both BAN2401 and aducanumab have shown encouraging phase 2 clinical results, the greater selectivity and avoidance of plaque binding with PMN310 may confer significant advantages in the clinic supporting  PMN310 as potential ‘best in class’ therapy.”

IHC is the process of selectively imaging antigens (e.g. proteins) in cells of a tissue section by exploiting the principle of antibodies (such as PMN310, aducanumab, BAN2401) binding specifically to their antigen targets in biological tissues. In the study referred to above, IHC was used to assess binding of Aβ-directed antibodies to Aβ plaque in AD brain tissue.

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing antibody therapeutics targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at:

Follow us on Twitter

Like us on LinkedIn

Media inquiries for ProMIS

David Schull
Tel. 858 717-2310

Investor Relations inquiries for ProMIS

Alpine Equity Advisors
Nicholas Rigopulos, President
Tel. 617 901-0785

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783

Media Inquiries for Selexis
Mike Beyer
Sam Brown Inc.

Tel. 312-961-2502

Company Inquiries for Selexis
Robert Meister
Head, Corporate Communications

Tel.  602-953-1716

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.  This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,  believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.